霍洛奇公司(纳斯达克代码：HOLX)获得券商一致给予的“适度买入”评级

Hologic, Inc. (NASDAQ:HOLX – Get Rating) has earned an average recommendation of "Moderate Buy" from the ten ratings firms that are covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $81.00.

A number of research analysts have recently commented on the company. Citigroup dropped their price target on Hologic from $78.00 to $75.00 in a research report on Thursday, April 28th. StockNews.com assumed coverage on shares of Hologic in a report on Thursday, March 31st. They set a "buy" rating on the stock. Wells Fargo & Company downgraded shares of Hologic from an "overweight" rating to an "equal weight" rating and dropped their price objective for the company from $90.00 to $75.00 in a report on Monday, April 25th. Finally, SVB Leerink upped their price objective on shares of Hologic to $85.00 and gave the company an "outperform" rating in a report on Tuesday, May 17th.

Get

Hologic

alerts:

Shares of HOLX opened at $70.19 on Wednesday. The company has a current ratio of 2.97, a quick ratio of 2.57 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $17.50 billion, a price-to-earnings ratio of 11.56, a PEG ratio of 0.88 and a beta of 1.09. The stock has a 50 day moving average of $73.20 and a 200 day moving average of $73.22. Hologic has a 12 month low of $66.58 and a 12 month high of $81.04.

Hologic (NASDAQ:HOLX – Get Rating) last issued its quarterly earnings results on Wednesday, April 27th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts' consensus estimates of $1.55 by $0.52. The company had revenue of $1.44 billion during the quarter, compared to the consensus estimate of $1.28 billion. Hologic had a return on equity of 42.26% and a net margin of 28.79%. During the same period last year, the business posted $2.59 earnings per share. As a group, equities research analysts predict that Hologic will post 5.54 earnings per share for the current year.

In other news, insider Jan Verstreken sold 6,500 shares of the company's stock in a transaction dated Tuesday, May 17th. The stock was sold at an average price of $78.80, for a total transaction of $512,200.00. Following the sale, the insider now directly owns 64,191 shares in the company, valued at $5,058,250.80. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 1.54% of the company's stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. American Trust increased its position in shares of Hologic by 31.9% during the first quarter. American Trust now owns 5,171 shares of the medical equipment provider's stock valued at $397,000 after buying an additional 1,252 shares during the period. Bank of America Corp DE increased its position in shares of Hologic by 10.0% in the first quarter. Bank of America Corp DE now owns 1,621,825 shares of the medical equipment provider's stock worth $124,587,000 after purchasing an additional 147,122 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Hologic by 23.8% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,154 shares of the medical equipment provider's stock worth $2,778,000 after purchasing an additional 6,948 shares during the last quarter. Walleye Capital LLC bought a new position in shares of Hologic in the first quarter worth approximately $264,000. Finally, Toroso Investments LLC increased its position in shares of Hologic by 7.4% in the first quarter. Toroso Investments LLC now owns 32,385 shares of the medical equipment provider's stock worth $2,488,000 after purchasing an additional 2,245 shares during the last quarter. Hedge funds and other institutional investors own 92.70% of the company's stock.

About Hologic (Get Rating)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.

Further Reading

• Get a free copy of the StockNews.com research report on Hologic (HOLX)
• Get Defensive With These Three Upgrades
• Looking to Dump These 3 Possible Delisted Chinese Stocks? Let's Take a Look.
• 3 Home Improvement Stocks That Can Renovate Your Portfolio
• Vera Bradley Stock Getting Cheap
• 3 Education Stocks to Enroll in This Summer

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.